Fig. 2: CBP/P300 activity is required for proper establishment of epigenetic landscape during ZGA.

A Track view of RNA-seq and spike-in ChIP-seq after CBP/P300 inhibitor treatment. Data from the previous study⁴ are shown with *. B Heatmap showing histone modification enrichment (spike-in ChIP-seq) around H3K27ac proximal peaks after CBP/P300 inhibitor treatment. C Quantification of (B). Boxplots indicate average of spike-in normalized enrichment of each histone modification in proximal H3K27ac peaks. Values above boxes indicate p values. Two-sided Wilcoxon rank-sum test. n = 703, 398 for CBP/P300-dependent, CBP/P300-independent, respectively. D Heatmap showing correlations between expression changes (RNA-seq) and changes in histone modification enrichment (spike-in ChIP-seq) after CBP/P300 inhibitor treatment. E Heatmap showing fold change of gene expression level and H3K4me2 enrichment in H3K27ac proximal peaks after inhibitor treatments. F Boxplot indicates the fold change of H3K4me2 enrichment in H3K27ac proximal peak after A485 treatment. Two-sided Wilcoxon rank-sum test. n = 703, 398 for CBP/P300-dependent, CBP/P300-independent, respectively. G Track view of RNA-seq and spike-in ChIP-seq after α-amanitin injection. Data from the previous study⁴ are shown with *. H Heatmap showing histone modification enrichment (spike-in ChIP-seq) around H3K27ac proximal peaks after α-amanitin injection. I Quantification of (H). Boxplots indicate average of spike-in normalized enrichment of each histone modification in H3K27ac proximal peaks. Values above boxes indicate p values. Two-sided Wilcoxon rank-sum test. n = 703, 398 for CBP/P300-dependent, CBP/P300-independent, respectively. J Heatmap showing fold change of gene expression level and histone modification enrichment in H3K27ac proximal peaks after α-amanitin injection. Box plots indicate median (middle line), 25th, 75th percentile (box) and 5th and 95th percentile (whiskers), and outliers are not shown. NS: not significant.